1. 2013 Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome. (September 2015) Authors: Teufel, M.; Kalmus, J.; Rutstein, M.; Köchert, K.; Seidel, H.; Reischl, J.; Skubula, A.; Vonk, R.; Wilhelm, S.; Kobina, S.; Qin, S.; Xu, R.; Kim, T.W.; Li, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S332 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2341 Tumor genotyping and clonal evolution in KIT during regorafenib treatment in the phase III GRID study of regorafenib vs placebo in tyrosine kinase inhibitor (TKI)-refractory GIST. (September 2015) Authors: Jeffers, M.; Beckmann, G.; Reischl, J.; Rutstein, M.; Wagner, A.; Demetri, G.D.; Teufel, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S448 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗